com_NN Discovery_NNP We_PRP continue_VBP to_TO increase_VB our_PRP$ efficiency_NN in_IN identifying_VBG high_JJ quality_NN compounds_NNS with_IN the_DT potential_JJ to_TO become_VB new_JJ medicines_NNS ._.
Jan_NNP Lundberg_NNP ,_, Executive_NNP Vice-President_NNP ,_, Discovery_NNP Research_NNP Every_DT new_JJ medicine_NN is_VBZ the_DT result_NN of_IN an_DT Medical_JJ research_NN is_VBZ more_RBR exciting_JJ than_IN intensive_JJ and_CC focused_VBD research_NN process_NN ._.
ever_RB as_IN new_JJ technology_NN is_VBZ applied_VBN to_TO We_PRP examine_VBP closely_RB all_PDT the_DT possibilities_NNS to_TO understanding_VBG what_WP causes_VBZ disease_NN find_VB the_DT most_RBS effective_JJ treatment_NN for_IN the_DT and_CC how_WRB it_PRP may_MD be_VB prevented_VBN or_CC treated_VBN ._.
Thousands_NNS of_IN Our_PRP$ effort_NN in_IN recent_JJ years_NNS to_TO improve_VB the_DT compounds_NNS are_VBP investigated_VBN ,_, only_RB a_DT small_JJ links_NNS between_IN basic_JJ science_NN and_CC clinical_JJ number_NN succeed_VB ._.
It_PRP is_VBZ a_DT complex_JJ ,_, expensive_JJ medicine_NN has_VBZ helped_VBN us_PRP to_TO gain_VB a_DT better_JJR and_CC risky_JJ process_NN taking_VBG over_RP 10_CD years_NNS understanding_NN of_IN human_JJ diseases_NNS and_CC and_CC typically_RB costing_VBG around_IN $_$ 1_CD billion_CD ,_, how_WRB future_JJ medicines_NNS will_MD work_VB against_IN but_CC it_PRP is_VBZ an_DT exciting_JJ and_CC rewarding_JJ one_CD ._.
We_PRP also_RB continue_VBP to_TO introduce_VB earlier_JJR in_IN the_DT process_NN more_RBR stringent_JJ ,_, We_PRP have_VBP a_DT world_NN leading_VBG R&D_NNP organization_NN ,_, and_CC where_WRB possible_JJ high_JJ throughput_NN ,_, with_IN over_IN 11,900_CD people_NNS at_IN 11_CD major_JJ centres_NNS testing_NN of_IN drug_NN safety_NN and_CC how_WRB a_DT medicine_NN in_IN seven_CD countries_NNS comprising_VBG six_CD joint_JJ gets_VBZ distributed_VBN around_RB ,_, and_CC out_RB ,_, of_IN the_DT discovery_NN and_CC development_NN facilities_NNS in_IN the_DT human_JJ body_NN ._.
This_DT helps_VBZ us_PRP to_TO eliminate_VB UK_NNP ,_, the_DT US_NNP and_CC Sweden_NNP :_: a_DT further_JJ four_CD earlier_JJR the_DT candidate_NN drugs_NNS CDs_NNS that_WDT sites_NNS in_IN the_DT US_NNP ,_, Canada_NNP ,_, India_NNP and_CC France_NNP are_VBP less_RBR likely_JJ to_TO succeed_VB ._.
During_IN 2004_CD ,_, which_WDT focus_VBP only_RB on_IN discovery_NN ,_, and_CC a_DT 18_CD CDs_NNS were_VBD selected_VBN for_IN development_NN ._.
facility_NN in_IN Japan_NNP for_IN development_NN only_RB ._.
These_DT resources_NNS are_VBP complemented_VBN by_IN Partnerships_NNS clinical_JJ development_NN at_IN 43_CD sites_NNS around_IN the_DT In_NNP todays_NNS world_NN of_IN rapid_JJ scientific_JJ and_CC world_NN ._.
We_PRP spend_VBP around_IN $_$ 15_CD million_CD each_DT technological_JJ advance_NN ,_, no_DT company_NN working_VBG day_NN in_IN the_DT search_NN for_IN new_JJ medicines_NNS ,_, can_MD rely_VB exclusively_RB on_IN its_PRP$ own_JJ discovery_NN and_CC we_PRP are_VBP committed_VBN to_TO delivering_VBG new_JJ ,_, and_CC development_NN ._.
We_PRP work_VBP with_IN leading_VBG medically_RB important_JJ and_CC commercially_RB academic_JJ centres_NNS to_TO broaden_VB the_DT successful_JJ products_NNS to_TO market_VB every_DT year_NN ._.
base_NN for_IN disease_NN research_NN and_CC during_IN 2004_CD ,_, we_PRP entered_VBD into_IN more_JJR than_IN 250_CD Discovery_NNP new_JJ collaborations_NNS ,_, including_VBG a_DT major_JJ Our_PRP$ Discovery_NNP scientists_NNS use_VBP leading_VBG edge_NN strategic_JJ alliance_NN with_IN Cambridge_NNP science_NN and_CC technologies_NNS to_TO identify_VB new_JJ Antibody_NNP Technology_NNP to_TO discover_VB and_CC compounds_VBZ with_IN high_JJ potential_NN as_IN new_JJ develop_VB human_JJ antibody_NN therapeutics_NNS in_IN medicines_NNS ,_, working_VBG across_IN boundaries_NNS inflammatory_JJ disorders_NNS ._.
This_DT complements_VBZ to_TO exchange_VB ideas_NNS ,_, to_TO share_VB best_JJS practice_NN a_DT similar_JJ alliance_NN in_IN cancer_NN research_NN with_IN and_CC to_TO make_VB the_DT most_JJS of_IN the_DT efficiencies_NNS Abgenix_NNP Inc._NNP announced_VBD in_IN 2003_CD ._.
that_IN global_JJ working_VBG offers_NNS ._.
